甲苯磺酸瑞马唑仑在颅内栓塞介入取栓术中的应用

doi:10.3760/cma.j.issn.1007-1245.2024.03.015

摘要/Abstract

摘要：

目的　研究甲苯磺酸瑞马唑仑在颅内血管栓塞患者介入取栓术麻醉中的疗效及安全性。方法　选取2021年10月至2023年3月聊城市第三人民医院收治的行颅内血管栓塞行介入取栓术患者进行随机对照试验，采用随机数字表法分为甲苯磺酸瑞马唑仑联合地佐辛组（R+D组）与丙泊酚联合地佐辛组（P+D组），各40例。R+D组中，男23例，女17例，年龄（61.7±7.4）岁；P+D组中，男21例，女19例，年龄（61.5±7.6）岁。比较两组患者疗效、不良反应、肾功能、炎症因子及T淋巴细胞差异，比较两组患者入室后（T0）、麻醉诱导完成后（T1）、麻醉维持（T2）、手术开始操作时（T3）、手术结束后（T4）及术毕苏醒时（T5）患者MAP、HR及SpO₂差异。采用独立样本t检验、χ²检验进行统计分析。结果　R+D组患者手术时间、苏醒时间、ICU入住时间、首次进食时间、下床活动时间、低血压、呼吸抑制、术中体动反应等并发症发生率均低于P+D组患者［（67.8±9.2）min比（81.4±10.6）min、（16.9±4.5）min比（27.1±5.2）min、（2.6±0.9）d比（3.9±1.1）d、（1.3±0.5）d比（1.8±0.7）d、（3.1±0.8）d比（4.6±1.1）d、12.5%（5/40）比40.0%（16/40）、12.5%（5/40）比37.5%（15/40）、7.5%（3/40）比35.0%（14/40）］，差异均有统计学意义（均P<0.05）。R+D组患者T1、T2、T3、T4、T5时MAP、HR及SpO₂水平低于P+D组患者。治疗后R+D组和P+D组患者hs-CRP、TNF-ａ、IL-6、CD3+、CD4+及CD8+均高于治疗前（均P<0.05）。治疗后，R+D组患者hs-CRP、TNF-α、IL-6、S100B及MBP均低于P+D组患者［（4.1±0.7）mg/L比（8.2±1.1）mg/L、（10.3±2.1）pg/L比（16.7±3.1）pg/L、（8.5±1.2）pg/L比（11.4±1.5）pg/L、（1.1±0.3）ng/L比（1.6±0.5）ng/L、（3.7±0.8）μg/L比（4.6±1.1）μg/L］，CD3+、CD4+及CD8+、Tau蛋白高于P+D组患者［（59.7±3.2）%比（56.1±2.8）%、（29.5±1.9）%比（27.3±1.8）%、（17.2±1.5）%比（15.4±1.4）%、（28.5±4.3）μg/L比（24.3±3.9）μg/L］，差异均有统计学意义（均P<0.05）。结论　甲苯磺酸瑞马唑仑在颅内血管栓塞行介入取栓术麻醉中具有镇静效果好及安全性高等优点，对患者炎症反应及免疫功能影响少。

关键词:

颅内血管栓塞, 介入取栓术, 甲苯磺酸瑞马唑仑, 疗效

Abstract:

Objective　To study the efficacy and safety of remimazolam tosylate in anesthesia for interventional thrombectomy for patients with intracranial vascular embolism. Methods　Eighty patients with intracranial vascular embolism who underwent interventional thrombectomy at Liaocheng Third People's Hospital from October 2021 to March 2023 were selected for the randomized controlled trial, and were divided into a mazolam combined with dezocine group (R+D group) and a propofol combined with dezocine group (P+D group) by the random number table method, with 40 cases in each group. There were 23 males and 17 males in the R+D group; they were (61.7±7.4) years old. There were 21 males and 19 females in the P+D group; they were (61.5±7.6) years old. The efficacies, adverse reactions, renal function, inflammatory factors, and T lymphocytes were compared between the R+D group and the P+D group. The mean artery pressures (MAP), heart rates (HR), and blood oxygen saturations (SpO₂) were compared between the two groups after entering the room (T0), after the completion of anesthesia induction (T1), during the maintenance of anesthesia (T2), at the beginning of the operation (T3), after the operation (T4), and when they woke up after the operation (T5). The independent-sample t test and χ² test were applied. Results　The operation time, recovery time, ICU time, first feeding time, time to get out of bed, and incidences of hypotension, respiratory depression, and intraoperative body movement reaction in the R+D group were all lower than those in the P+D group [(67.8±9.2) min vs. (81.4±10.6) min, (16.9±4.5) min vs. (27.1±5.2) min, (2.6±0.9) d vs. (3.9±1.1) d, (1.3±0.5) d vs. (1.8±0.7) d, (3.1±0.8) d vs. (4.6±1.1) d, 12.5% (5/40) vs. 40.0% (16/40), 12.5% (4/40) vs. 37.5% (15/40), and 7.5% (3/40) vs. 35.0% (14/40)], with statistical differences (all P<0.05). The MAP, HR, and SpO₂ at T1, T2, T3, T4, and T5 in the R+D group were lower than those in the P+D group. After the treatment, the levels of hs-CRP, TNF-α, IL-6, S100B, and MBP in the R+D group were lower than those in the P+D group [(4.1±0.7) mg/L vs. (8.2±1.1) mg/L, (10.3±2.1) pg/L vs. (16.7±3.1) pg/L, (8.5±1.2) pg/L vs. (11.4±1.5) pg/L, (1.1±0.3) ng/L vs. (1.6±0.5) ng/L, and (3.7±0.8) μg/L vs. (4.6±1.1) μg/L]; the levels of CD3+, CD4+, CD8+, and Tau protein in the R+D group were higher than those in the P+D group [(59.7±3.2)% vs. (56.1±2.8)%, (29.5±1.9)% vs. (27.3±1.8)%, (17.2±1.5)% vs. (15.4±1.4)%, and (28.5±4.3) μg/L vs. (24.3±3.9) μg/L]; there were statistical differences (all P<0.05). Conclusion Remimazolam tosylate has the advantages of good sedation effect and high safety in anesthesia for interventional thrombectomy for patients with intracranial vascular embolization, and has little impact on the patients' inflammatory response and immune function.

Key words:

Intracranial vascular embolism, Interventional thrombectomy, Remimazolam tosylate, Curative effect

胡洪凭张月霄张洪凯王景伟杨嘉甫.

甲苯磺酸瑞马唑仑在颅内栓塞介入取栓术中的应用 [J]. 国际医药卫生导报, 2024, 30(3): 424-429.

Hu Hongping, Zhang Yuexiao, Zhang Hongkai, Wang Jingwei, Yang Jiafu.

Application of remimazolam tosylate in interventional thrombectomy for patients with intracranial embolization [J]. International Medicine and Health Guidance News, 2024, 30(3): 424-429.

参考文献

[1] Lu SY, Dalia AA, Lang M, et al. Perioperative outcomes of thrombectomy patients using venovenous bypass and suction filtration with general anesthesia[J]. J Cardiothorac Vasc Anesth, 2021,35(4):1040-1045. DOI: 10.1053/j.jvca.2020.09.104.
[2] Mohammaden MH, Haussen DC, Al-Bayati AR, et al. General anesthesia vs procedural sedation for failed NeuroThrombectomy undergoing rescue stenting: intention to treat analysis[J]. J Neurointerv Surg, 2023,15(e2):e240-e247. DOI: 10.1136/jnis-2022-019376.
[3] Fang YB, Wang CY, Gao YQ, et al. The safety and efficacy of remimazolam tosylate for induction and maintenance of general anesthesia in pediatric patients undergoing elective surgery: study protocol for a multicenter, randomized, single-blind, positive-controlled clinical trial[J]. Front Pharmacol, 2023,14:1090608. DOI: 10.3389/fphar.2023.1090608.
[4] 朱伟波,于建民,王建越,等.不同剂量甲苯磺酸瑞马唑仑对经肠道内镜黏膜下剥离术者抗感染效果分析[J].临床和实验医学杂志,2022,21(22):2462-2464,后插1.DOI:10.3969/j.issn.1671-4695.2022.22.030.
[5] Chen S, Wang J, Xu X, et al. The efficacy and safety of remimazolam tosylate versus propofol in patients undergoing colonoscopy: a multicentered, randomized, positive-controlled, phase III clinical trial[J]. Am J Transl Res, 2020,12(8):4594-4603.
[6] Zhang F, Chang H, Qing W, et al. Remimazolam tosylate combined with low-dose propofol improves sedation and safety in hysteroscopy[J]. Drug Des Devel Ther, 2022,16:4101-4108. DOI: 10.2147/DDDT.S390403.
[7] 赵晓咏.甲苯磺酸瑞马唑仑在全麻诱导与维持中的安全性与有效性研究[D]. 荆州:长江大学,2022.
[8] Lv L, Yan L, Liu X, et al. Effectiveness of lidocaine/prilocaine cream on cardiovascular reactions from endotracheal intubation and cough events during recovery period of older patients under general anesthesia: prospective, randomized placebo-controlled study[J]. BMC Geriatr, 2020,20(1):157. DOI: 10.1186/s12877-020-01567-y.
[9] 都淑萍,王晓东,潘红霞,等.右美托咪定、丙泊酚联合小剂量艾司氯胺酮在宫腔镜手术中的临床应用[J].国际医药卫生导报,2022,28(15):2093-2097.DOI:10.3760/cma.j.issn.1007-1245.2022.15.005.
[10] Zhang S, Wang J, Ran R, et al. Efficacy and safety of remimazolam tosylate in hysteroscopy: a randomized, single-blind, parallel controlled trial[J]. J Clin Pharm Ther, 2022,47(1):55-60. DOI: 10.1111/jcpt.13525.
[11] Zheng X, Ji J, Cheng H, et al. Efficacy and safety of different doses of remimazolam tosylate for colonoscopy: single-center, prospective, randomized, double-blind, parallel trial[J]. Ann Transl Med, 2022,10(22):1244. DOI: 10.21037/atm-22-5133.
[12] Yao Z, Liao Z, Li G, et al. Remimazolam tosylate's long-term sedative properties in ICU patients on mechanical ventilation: effectiveness and safety[J]. Eur J Med Res, 2023,28(1):452. DOI: 10.1186/s40001-023-01440-9.
[13] Liu X, Guo L, Duan B, et al. Novel benzodiazepine remimazolam tosylate delays neurodegeneration of aged mice Via decreasing Tau phosphorylation[J]. Neurotoxicology, 2022,92:156-165. DOI: 10.1016/j.neuro.2022.08.003.
[14] Zhu H, Su Z, Huai X, et al. Efficacy and safety of remimazolam tosylate for sedation during upper gastrointestinal endoscopy: study protocol for a multicenter randomized controlled trial[J]. Trials, 2022,23(1):995. DOI: 10.1186/s13063-022-06935-0.
[15] Pambianco DJ, Borkett KM, Riff DS, et al. A phase IIb study comparing the safety and efficacy of remimazolam and midazolam in patients undergoing colonoscopy[J]. Gastrointest Endosc, 2016,83(5):984-92. DOI: 10.1016/j.gie.2015.08.062.
[16] Rex DK, Bhandari R, Desta T, et al. A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy[J]. Gastrointest Endosc, 2018,88(3):427-437.e6. DOI: 10.1016/j.gie.2018.04.2351.
[17] 桂雨农,姜超,徐中菊.缺血性脑梗死后免疫机制的研究进展[J].中西医结合心脑血管病杂志,2022,20(16):2971-2975.DOI:10.12102/j.issn.1672-1349.2022.16.018.
[18] 龚朝霞.全身免疫炎症指数(SII)与2型糖尿病合并非心源性急性脑梗死的相关性研究[D]. 南昌:南昌大学医学部,2022.
[19] 李巍,王莉莉.中性粒细胞与淋巴细胞比值和系统免疫炎症指数对急性脑梗死患者卒中相关性肺炎的诊断价值[J].中华老年心脑血管病杂志,2021,23(9):968-971.DOI:10.3969/j.issn.1009-0126.2021.09.019.
[20] 何霞,崔璨,陈敏.骨髓间充质干细胞移植对实验性大鼠缺血性脑梗死免疫炎性反应的影响研究[J].中国免疫学杂志,2018,34(5):647-652.DOI:10.3969/j.issn.1000- 484X. 2018.05.002.
[21] 黄杰,万金丽,谢伟贤.基于外周血免疫分子参数建立的Fisher判别模型对进展性脑梗死的诊断价值[J].山东医药,2020,60(25):56-58.DOI:10.3969/j.issn.1002- 266X. 2020.25.015.
[22] 王文盛,吕荣祥,张静静,等.急性脑梗死医院感染患者炎性因子和免疫功能变化[J].中华医院感染学杂志,2020,30(16):2461-2465.DOI:10.11816/cn.ni.2020-192582.
[23] 何谦益,石晓娟,连晶瑶,等.脑梗死患者外周血CD4+T细胞表面PD-1、Tim-3和CTLA-4的表达[J].现代免疫学,2020,40(6):476-481.
[24] 贾光辉,娄渊和,张丙强,等.毫针穴位针刺联合面瘫散口服治疗急性周围性面神经麻痹效果观察[J].山东医药,2023,63(5):78-80.DOI:10.3969/j.issn.1002-266X.2023.05.019.
[25] 陈伟,凌艳,王永盛.脑梗死后肺部感染外周血CD4+T细胞表面PD-1/PD-L1表达的意义[J].中华医院感染学杂志,2021,31(23):3537-3541.DOI:10.11816/cn.ni.2021- 210213.
[26] Oris C, Pereira B, Durif J, et al. The biomarker S100B and mild traumatic brain injury: a meta-analysis[J]. Pediatrics, 2018,141(6):e20180037. DOI: 10.1542/peds.2018-0037.
[27] Amoo M, Henry J, O'Halloran PJ, et al. S100B, GFAP, UCH-L1 and NSE as predictors of abnormalities on CT imaging following mild traumatic brain injury: a systematic review and meta-analysis of diagnostic test accuracy[J]. Neurosurg Rev, 2022,45(2):1171-1193. DOI: 10.1007/s10143-021-01678-z.
[28] Zou Z, Li L, Li Q, et al. The role of S100B/RAGE-enhanced ADAM17 activation in endothelial glycocalyx shedding after traumatic brain injury[J]. J Neuroinflammation, 2022,19(1):46. DOI: 10.1186/s12974-022-02412-2.
[29] Martinez BI, Stabenfeldt SE. Current trends in biomarker discovery and analysis tools for traumatic brain injury[J]. J Biol Eng, 2019,13:16. DOI: 10.1186/s13036-019-0145-8.
[30] Edwards G, Zhao J, Dash PK, et al. Traumatic brain injury induces Tau aggregation and spreading[J]. J Neurotrauma, 2020,37(1):80-92. DOI: 10.1089/neu. 2018.6348.
[31] Li L, Liang J, Fu H. An update on the association between traumatic brain injury and Alzheimer's disease: focus on Tau pathology and synaptic dysfunction[J]. Neurosci Biobehav Rev, 2021,120:372-386. DOI: 10.1016/j.neubiorev.2020.10.020.